CP 461 | 227619-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: CP 461
• 英文别名: N-benzyl-2-[5-fluoro-2-methyl-1-[(z)-(pyridin-4-yl)methylene]-1H-inden-3-yl]acetamide hydrochloride；N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide;hydron;chloride
• CAS: 227619-96-7
• 化学式: C₂₅H₂₁FN₂O*ClH
• 分子量: 420.914
• InChiKey: KGXPDNOBLLACKL-BWLGBDCWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.68
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  42
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS
  申请人：PEUKER Heidemarie

  公开号：US20110142956A1

  公开（公告）日：2011-06-16

  The invention relates to the use of PDE5 inhibitors for treating and/or preventing hypopigmentary disorders.

  本发明涉及使用PDE5抑制剂来治疗和/或预防低色素病。
• Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
  申请人：Switch Biotech Aktiengesellschaft

  公开号：EP1759700A1

  公开（公告）日：2007-03-07

  The invention relates to the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary disorders.

  本发明涉及 PDE5 抑制剂（最好是西地那非或他达拉非）在治疗和/或预防色素减退症方面的用途，可选择与另一种活性成分结合使用。
• BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE
  申请人：ARKRAY, Inc.

  公开号：EP3575791A1

  公开（公告）日：2019-12-04

  The method for treating collected blood to be used in a test for rare cells in blood, includes mixing the collected blood with an agent that increases the intracellular concentration of cAMP or an analogous compound thereof. The method for performing a test for rare cells in blood, includes using blood treated using the method according to the present disclosure as a blood sample to be subjected to the test.

  处理采集的血液以用于检测血液中的稀有细胞的方法包括将采集的血液与增加细胞内cAMP或其类似化合物浓度的药剂混合。进行血液中稀有细胞检测的方法，包括使用根据本公开的方法处理过的血液作为要进行检测的血样。
• Medical devices to prevent or inhibit restenosis
  申请人：Hezi-Yamit Ayala

  公开号：US20050261762A1

  公开（公告）日：2005-11-24

  Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain anti-inflammatory agents, are disclosed. The-anti-inflammatory agents are selected from the group consisting of ENMD-0997, gusperimus hydrochloride, BMS-561392, CP-461, RDP-58, CNI-1493, CEP-1347, CMT-3, prinomastat, rebimastat, leflunomide, BX-471, DF-1681, BXT-51072, M-40403, LY-293111 sodium, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the anti-inflammatory agent with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-anti-inflammatory agent blends are disclosed. Medical devices having a coating comprising at least one anti-inflammatory agent in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are disclosed.

  本研究公开了具有抗血管狭窄涂层的植入式医疗器械。具体而言，本发明公开了具有某些抗炎剂涂层的植入式医疗器械。这些抗炎剂选自ENMD-0997、盐酸古培利莫、BMS-561392、CP-461、RDP-58、CNI-1493、CEP-1347、CMT-3、普利莫司他、瑞比莫司他、来氟米特、BX-471、DF-1681、BXT-51072、M-40403、LY-293111钠及其药学上可接受的衍生物组成的组。抗血管再狭窄医疗器械包括支架、导管、微颗粒、探针和血管移植物。血管内支架是首选的医疗器械。这些医疗器械可以使用本领域已知的任何方法进行涂布，包括在涂布前将消炎剂与生物相容性聚合物复合。此外，还公开了完全由生物相容性聚合物-消炎剂混合物组成的医疗器械。还公开了具有包含至少一种消炎剂和至少一种额外治疗剂的涂层的医疗器械。此外，还公开了使用和制造抗再狭窄植入装置的相关方法。
• Composition comprising a pulmonary surfactant and a pde2 inhibitor
  申请人：Wollin Stefan-Lutz

  公开号：US20060229242A1

  公开（公告）日：2006-10-12

  The invention relates to the combined administration of a pulmonary surfactant and a PDE2 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 2 (PDE2) activity is detrimental.

  本发明涉及肺表面活性物质和PDE2抑制剂的联合用药，用于治疗肺表面活性物质功能失调和/或磷酸二酯酶2（PDE2）活性低下的疾病。